New vaccine formulation protects newborn mice against respiratorysyncytialvirus (RSV) bostonchildrens J_Immunol NatureComms
"Consequently, pediatric vaccine development was halted, recognizing that the
and different combinations of vaccine adjuvants that might stimulate these receptors, making vaccination more effective.that a combination of two potential adjuvants, stimulating the TLR7/8 and Mincle receptors, provoked robust responses in newborns' antigen-presenting cells, critical for kickstarting cellular immune defenses. They saw strong activation of type 1 T-helper responses.
The team first administered the CAF-08/RSV vaccine to cultured antigen-presenting cells obtained from donated cord blood from human newborns. Led by Hanno Steen, Ph.D., at Boston Children's, the researchers comprehensively profiled the cells' responses with phosphoproteomics. This revealed enhanced production of cytokines by Th1 cells and other indicators of a robust immune response.